Fulcrum Therapeutics (FULC) Income towards Parent Company: 2020-2025
Historic Income towards Parent Company for Fulcrum Therapeutics (FULC) over the last 5 years, with Sep 2025 value amounting to -$19.6 million.
- Fulcrum Therapeutics' Income towards Parent Company rose 9.68% to -$19.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$75.5 million, marking a year-over-year decrease of 321.56%. This contributed to the annual value of -$9.7 million for FY2024, which is 90.01% up from last year.
- Per Fulcrum Therapeutics' latest filing, its Income towards Parent Company stood at -$19.6 million for Q3 2025, which was down 10.99% from -$17.7 million recorded in Q2 2025.
- In the past 5 years, Fulcrum Therapeutics' Income towards Parent Company registered a high of $55.4 million during Q2 2024, and its lowest value of -$34.1 million during Q2 2022.
- For the 3-year period, Fulcrum Therapeutics' Income towards Parent Company averaged around -$14.4 million, with its median value being -$22.7 million (2023).
- In the last 5 years, Fulcrum Therapeutics' Income towards Parent Company spiked by 332.98% in 2024 and then crashed by 131.86% in 2025.
- Quarterly analysis of 5 years shows Fulcrum Therapeutics' Income towards Parent Company stood at -$23.5 million in 2021, then decreased by 11.29% to -$26.1 million in 2022, then grew by 5.28% to -$24.8 million in 2023, then soared by 33.07% to -$16.6 million in 2024, then climbed by 9.68% to -$19.6 million in 2025.
- Its last three reported values are -$19.6 million in Q3 2025, -$17.7 million for Q2 2025, and -$16.6 million during Q4 2024.